8-K: Lyell Immunopharma to Acquire ImmPACT Bio, Prioritizes Pipeline for Next-Gen CAR T-Cell Therapies

Lyell Immunopharma will acquire ImmPACT Bio, adding a dual-targeting CAR T-cell therapy to its pipeline and focusing on next-generation CAR T-cell programs.

Summary

• Lyell Immunopharma has agreed to acquire ImmPACT Bio for an upfront payment of $30 million in cash, subject to adjustments, and 37.5 million shares of Lyell common stock.
• ImmPACT shareholders may also receive 12.5 million shares of Lyell stock upon achieving a clinical milestone and a low single-digit royalty on future net sales of the dual-targeting CD19/20 CAR T-cell product in the United States.
• Lyell is prioritizing its pipeline to focus on next-generation CAR T-cell therapies, including IMPT-314 and LYL119, and discontinuing development of LYL797, LYL845, and earlier-stage TIL programs.
• The acquisition is expected to strengthen Lyell's clinical pipeline and extend its cash runway into 2027.
• IMPT-314 is a dual-targeting CD19/20 CAR T-cell product candidate designed to improve efficacy and persistence compared to approved CD19 CAR T-cell therapies.
• Lyell expects to initiate a pivotal trial for IMPT-314 in 2025 for patients in the 3rd line setting who have not yet been exposed to CAR T-cell therapy.
• Initial Phase 1-2 clinical data for IMPT-314 will be presented at a major medical conference later this year.

Sentiment

Score: 8

Explanation: The document is positive due to the strategic acquisition, pipeline prioritization, and promising clinical data for IMPT-314. The focus on next-generation CAR T-cell therapies and the extended cash runway are also viewed favorably.

Positives

• The acquisition of ImmPACT Bio strengthens Lyell's clinical pipeline with a promising dual-targeting CAR T-cell therapy.
• The prioritization of the pipeline allows Lyell to focus resources on its most differentiated CAR T-cell programs.
• The extended cash runway into 2027 provides financial stability for Lyell to achieve important clinical milestones.
• IMPT-314 has shown promising early clinical data, suggesting potential for improved efficacy compared to existing therapies.
• The initiation of a pivotal trial for IMPT-314 in 2025 represents a significant step forward in its development.

Negatives

• Lyell is discontinuing development of LYL797, LYL845, and earlier-stage TIL programs, which may impact its long-term pipeline diversity.
• The clinical data for LYL845 did not meet Lyell's criteria for continued development.

Risks

• The acquisition is subject to customary closing conditions, including the expiration of the Hart-Scott-Rodino antitrust waiting period.
• There are risks associated with the integration of ImmPACT Bio and the development of IMPT-314.
• Clinical trial results may differ from preclinical or early clinical data.
• There is uncertainty associated with obtaining regulatory approvals for Lyell's product candidates.
• Lyell may need additional capital to achieve its goals beyond the current cash runway.

Future Outlook

Lyell expects to initiate a pivotal trial for IMPT-314 in 2025 and anticipates its cash balance will fund operations into 2027, through important clinical milestones for each pipeline program.

Management Comments

• Lynn Seely, M.D., Lyell's President and Chief Executive Officer, stated that the acquisition will bring meaningful and durable clinical benefit to patients suffering from cancer with their next-generation cell therapies.
• Sumant Ramachandra, M.D., Ph.D., Chief Executive Officer of ImmPACT, expressed confidence that Lyell shares their passion for advancing novel science to benefit patients.

Industry Context

This acquisition reflects a trend in the biotechnology industry towards consolidation and pipeline prioritization, particularly in the competitive field of CAR T-cell therapy. Lyell is focusing on next-generation technologies to improve efficacy and durability, which is a key area of innovation in the field.

Comparison to Industry Standards

• The acquisition of ImmPACT Bio by Lyell Immunopharma is similar to other acquisitions in the biotech space where larger companies acquire smaller firms with promising clinical assets.
• The focus on dual-targeting CAR T-cell therapies like IMPT-314 is a response to the limitations of existing CD19 CAR T-cell therapies, which have shown variable efficacy and durability.
• The reported 77% complete response rate in the UCLA-sponsored Phase 1 trial of IMPT-314 is higher than the typical response rates seen with approved CD19 CAR T-cell therapies in similar patient populations, such as Kymriah and Yescarta, which have shown complete response rates in the 30-40% range in relapsed/refractory large B-cell lymphoma.
• The median progression-free survival of 50.1 months in the UCLA trial is also significantly longer than the typical progression-free survival seen with approved CD19 CAR T-cell therapies, which is often in the range of 6-12 months.
• Lyell's decision to discontinue LYL797 and LYL845 is consistent with industry practice of prioritizing resources on the most promising clinical programs and cutting programs that do not meet pre-determined criteria for continued development, similar to decisions made by other companies in the CAR T-cell space such as Juno Therapeutics and Kite Pharma.

Stakeholder Impact

• Shareholders of Lyell Immunopharma will see a strengthened clinical pipeline and extended cash runway.
• Patients with hematologic malignancies may benefit from the development of new and improved CAR T-cell therapies.
• Employees of ImmPACT Bio will transition to Lyell Immunopharma.
• Employees of Lyell will see a change in focus of the pipeline.

Next Steps

• Lyell will present initial Phase 1-2 clinical data for IMPT-314 at a major medical conference later this year.
• Lyell expects to initiate a pivotal trial for IMPT-314 in 2025.
• Lyell will continue to advance the development of LYL119.

Key Dates

Keywords

CAR T-cell therapy, Lyell Immunopharma, ImmPACT Bio, IMPT-314, LYL119, hematologic malignancies, B-cell lymphoma, clinical trial, acquisition, pipeline prioritization